ストックスクリーナーアプリを入手
5.97
5.54%
-0.35
アフターアワーズ：
5.97
前日終値:
$6.32
開ける：
$6.18
24時間の取引高:
387.91K
Relative Volume:
1.26
時価総額：
$256.09M
収益：
$127.70M
当期純損益:
$-121.25M
株価収益率:
-1.8952
EPS:
-3.15
ネットキャッシュフロー:
$-120.32M
1週間 パフォーマンス:
-13.35%
1か月 パフォーマンス:
-17.77%
6か月 パフォーマンス:
-41.53%
1年 パフォーマンス:
-56.23%
1日の値動き範囲:
$5.85
$6.21
1週間の範囲:
$5.85
$6.87
52週間の値動き範囲:
$5.85
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
ITOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
5.97 | 256.09M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | 開始されました | Wells Fargo | Overweight |
| 2021-05-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | SVB Leerink | Outperform |
| 2020-08-18 | 開始されました | Wedbush | Outperform |
すべてを表示
Iteos Therapeutics Inc (ITOS) 最新ニュース
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Virtu Financial LLC - Defense World
Charles Schwab Investment Management Inc. Sells 22,939 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Bank of New York Mellon Corp Sells 35,918 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc Stock: Cancer Drug Pipeline Shows Promise - Sharewise
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewswire
Game-Changing Cancer Drug Data: iTeos Reveals Best-in-Class Antibody Results at AACR - Stock Titan
Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com
Victory Capital Management Inc. Has $782,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - Yahoo Finance
(ITOS) Investment Report - news.stocktradersdaily.com
Research Analysts Offer Predictions for ITOS Q1 Earnings - Defense World
Analysts Set Expectations for ITOS FY2029 Earnings - Defense World
Wells Fargo & Company Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
JPMorgan Chase & Co. Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape - TipRanks
iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush - Defense World
iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2024 - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on ITOS with $21 price target By Investing.com - Investing.com Canada
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations - Simply Wall St
iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position - TipRanks
Y Intercept Hong Kong Ltd Purchases Shares of 18,468 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Iteos Therapeutics Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
iTeos Therapeutics, Inc. SEC 10-K Report - TradingView
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Can iTeos' $655M War Chest Deliver on Its Promising Cancer Immunotherapy Pipeline? - StockTitan
iTeos Therapeutics (ITOS) to Release Earnings on Wednesday - Defense World
ITOS stock touches 52-week low at $7.09 amid market challenges - MSN
(ITOS) Technical Pivots with Risk Controls - Stock Traders Daily
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
Iteos Therapeutics stock hits 52-week low at $7.05 By Investing.com - Investing.com Canada
Iteos Therapeutics stock hits 52-week low at $7.05 - Investing.com India
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat
Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World
(ITOS) Investment Analysis and Advice - Stock Traders Daily
Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat
(ITOS) Proactive Strategies - Stock Traders Daily
Iteos Therapeutics Inc (ITOS) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):